Search research articles
Contact Us
Filters
Showing results (71-80 of 94) with videos related to
Page
of 10
Sort By:
JACC. Cardiovascular Imaging
|
February 8, 2018
Feasibility Evaluation of Myocardial Cannabinoid Type 1 Receptor Imaging in Obesity: A Translational Approach
Ines Valenta, Zoltan V Varga, Heather Valentine, et al.
Iscience
|
August 3, 2023
Cannabinoid receptor type 1 (CB<sub>1</sub>R) inhibits hypothalamic leptin signaling via β-arrestin1 in complex with TC-PTP and STAT3
Gergő Szanda, Tony Jourdan, Éva Wisniewski, et al.
Hepatology (Baltimore, Md.)
|
April 10, 2018
Disruption of Renal Arginine Metabolism Promotes Kidney Injury in Hepatorenal Syndrome in Mice
Zoltan V Varga, Katalin Erdelyi, Janos Paloczi, et al.
Chemistry & Biology
|
November 25, 2010
Inhibitor of fatty acid amide hydrolase normalizes cardiovascular function in hypertension without adverse metabolic effects
Grzegorz Godlewski, Shakiru O Alapafuja, Sándor Bátkai, et al.
Respiratory Research
|
May 5, 2022
Progressive pulmonary fibrosis in a murine model of Hermansky-Pudlak syndrome
Shachar Abudi-Sinreich, Steven P Bodine, Tadafumi Yokoyama, et al.
ACS Pharmacology & Translational Science
|
June 21, 2021
Functional Selectivity of a Biased Cannabinoid-1 Receptor (CB<sub>1</sub>R) Antagonist
Ziyi Liu, Malliga R Iyer, Grzegorz Godlewski, et al.
Cell Metabolism
|
July 31, 2012
Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance
Joseph Tam, Resat Cinar, Jie Liu, et al.
Medrxiv : the Preprint Server for Health Sciences
|
May 27, 2024
Anandamide is an Early Blood Biomarker of Hermansky-Pudlak Syndrome Pulmonary Fibrosis
Resat Cinar, Abhishek Basu, Muhammad Arif, et al.
American Journal of Respiratory and Critical Care Medicine
|
January 22, 2025
Anandamide Is a Potential Blood Biomarker of Hermansky-Pudlak Syndrome Pulmonary Fibrosis
Resat Cinar, Abhishek Basu, Muhammad Arif, et al.
British Journal of Pharmacology
|
September 24, 2015
The novel, orally available and peripherally restricted selective cannabinoid CB2 receptor agonist LEI-101 prevents cisplatin-induced nephrotoxicity
Partha Mukhopadhyay, Marc Baggelaar, Katalin Erdelyi, et al.
Page
of 10
Search research articles
Search
Showing results (71-80 of 94) with videos related to
Sort By:
Page
of 10
JACC. Cardiovascular Imaging
|
February 8, 2018
Feasibility Evaluation of Myocardial Cannabinoid Type 1 Receptor Imaging in Obesity: A Translational Approach
Ines Valenta, Zoltan V Varga, Heather Valentine, et al.
Iscience
|
August 3, 2023
Cannabinoid receptor type 1 (CB<sub>1</sub>R) inhibits hypothalamic leptin signaling via β-arrestin1 in complex with TC-PTP and STAT3
Gergő Szanda, Tony Jourdan, Éva Wisniewski, et al.
Hepatology (Baltimore, Md.)
|
April 10, 2018
Disruption of Renal Arginine Metabolism Promotes Kidney Injury in Hepatorenal Syndrome in Mice
Zoltan V Varga, Katalin Erdelyi, Janos Paloczi, et al.
Chemistry & Biology
|
November 25, 2010
Inhibitor of fatty acid amide hydrolase normalizes cardiovascular function in hypertension without adverse metabolic effects
Grzegorz Godlewski, Shakiru O Alapafuja, Sándor Bátkai, et al.
Respiratory Research
|
May 5, 2022
Progressive pulmonary fibrosis in a murine model of Hermansky-Pudlak syndrome
Shachar Abudi-Sinreich, Steven P Bodine, Tadafumi Yokoyama, et al.
ACS Pharmacology & Translational Science
|
June 21, 2021
Functional Selectivity of a Biased Cannabinoid-1 Receptor (CB<sub>1</sub>R) Antagonist
Ziyi Liu, Malliga R Iyer, Grzegorz Godlewski, et al.
Cell Metabolism
|
July 31, 2012
Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance
Joseph Tam, Resat Cinar, Jie Liu, et al.
Medrxiv : the Preprint Server for Health Sciences
|
May 27, 2024
Anandamide is an Early Blood Biomarker of Hermansky-Pudlak Syndrome Pulmonary Fibrosis
Resat Cinar, Abhishek Basu, Muhammad Arif, et al.
American Journal of Respiratory and Critical Care Medicine
|
January 22, 2025
Anandamide Is a Potential Blood Biomarker of Hermansky-Pudlak Syndrome Pulmonary Fibrosis
Resat Cinar, Abhishek Basu, Muhammad Arif, et al.
British Journal of Pharmacology
|
September 24, 2015
The novel, orally available and peripherally restricted selective cannabinoid CB2 receptor agonist LEI-101 prevents cisplatin-induced nephrotoxicity
Partha Mukhopadhyay, Marc Baggelaar, Katalin Erdelyi, et al.
Page
of 10